Patient‐Derived Glioblastoma Organoids for AI‐Guided Prediction of Therapeutic Response
Advanced Science · 2026-11-09
DOI: 10.1002/advs.78202 ↗At a glance
Übersichtsarbeit in Advanced Science, published online on 2026-11-09. Written by Sandbhor Puja and 15 co-authors. Institution: Translational Nanomedicine and Bioengineering Lab, Proton Therapy Centre, Department of Radiation Oncology, Clinical Research Centre (CRC), Advanced …. 297 references. The full text is freely available (open access, CC BY 4.0). Funded by: Inspire Faculty Fellowship, Department of Science and Technology (DST), Ministry of Science and Technology, New Delhi, India.
Abstract (original language)
Glioblastoma (GBM) remains one of the most treatment‐refractory brain tumors, with poor survival driven by intratumoral heterogeneity, adaptive therapy resistance, and an immunosuppressive microenvironment that conventional preclinical models have failed to capture. Although these systems offer partial biological insights, none simultaneously preserve patient‐specific tumor architecture, microenvironmental complexity, and scalability needed for translational research. Patient‐derived GBM organoids address this gap by recapitulating 3D tumor architecture, glioma stem cell (GSC) hierarchies, extracellular matrix (ECM) interactions, and clinically relevant drug response phenotypes in a human‐specific system. This review examines GBM organoid biology and engineering, from GSC isolation and ECM scaffold design to maturation, vascular integration, and immune co‐culture. We discuss established platforms including NeoCOR and GLICO, and the rationale for incorporating functional vasculature, tumor‐immune microenvironment components, blood‐brain‐barrier (BBB), and blood‐cerebrospinal fluid barrier (BCSFB) interfaces. Critically, we propose that integrating artificial‐intelligence (AI) and machine learning (ML) with GBM organoid platforms represents a major opportunity in the field. Convolutional neural networks, ML‐based multi‐omics integration, drug‐genome correlation analysis, and predictive modelling of therapy resistance can transform organoid readouts into clinically actionable decisions. This AI‐organoid framework offers a path toward real‐time, patient‐specific therapy selection, supporting precision‐oncology workflows, informing clinical trial design, and reducing GBM therapy failure.
Subjects
Author keywords
Authors and institutions
- Translational Nanomedicine and Bioengineering Lab, Proton Therapy Centre, Department of Radiation Oncology, Clinical Research Centre (CRC), Advanced Centre for Treatment, Research, and Education in Cancer-Tata Memorial…
- Hasan Lab, Advanced Centre for Treatment, Research, and Education in Cancer -Tata Memorial Centre (ACTREC-TMC), Cancer Research Institute (CRI), Navi-Mumbai, India.
- Future Industries Institute, School of Pharmacy and Biomedical Science, College of Health, Adelaide University, Adelaide, South Australia.
- Radiobiology Lab, Department of Radiation Oncology, Clinical Research Centre (CRC) and Homi Bhabha National Institute and Advanced Centre for Treatment, Research and Education in Cancer- Tata Memorial Centre (ACTREC-TMC…
- Department of Neurosurgery, Tata Memorial Centre, Homi Bhabha National Institute, Dr. E. Borges Marg, Mumbai, India.
- Department of Pathology, Tata Memorial Centre, Homi Bhabha National Institute, Dr. E. Borges Marg, Mumbai, India.
ORCID profiles: Sandbhor Puja, Arun Bhavyadharshini, John Geofrey, Mudliyar Siddharth, Ghanekar Shubham, Singh Vikas, Chatterjee Abhishek, Epari Sridhar, Dasgupta Archya, Goda Jayant
Funding
- Inspire Faculty Fellowship
- Department of Science and Technology (DST)
- Ministry of Science and Technology, New Delhi, India
- Tata Memorial Hospital Intramural Research Grant
- Prime Minister Early Career Research Fellowship
- Anusandhan National Research Foundation (ANRF) program
Cite
APA
Puja, S., Bhavyadharshini, A., Geofrey, J., Siddharth, M., Shubham, G., Aliasgar, M., Prakash, S., Vikas, S., Nidhisha, S., Akshohini, G., Ayushi, S., Abhishek, C., Sridhar, E., Tejpal, G., Archya, D., & Jayant, G. (2026). Patient‐Derived Glioblastoma Organoids for AI‐Guided Prediction of Therapeutic Response. Advanced Science. https://doi.org/10.1002/advs.78202
Vancouver
Puja S, Bhavyadharshini A, Geofrey J, Siddharth M, Shubham G, Aliasgar M, et al. Patient‐Derived Glioblastoma Organoids for AI‐Guided Prediction of Therapeutic Response. Advanced Science. 2026. doi:10.1002/advs.78202
BibTeX
@article{Puja2026,
author = {Puja, Sandbhor and Bhavyadharshini, Arun and Geofrey, John and Siddharth, Mudliyar and Shubham, Ghanekar and Aliasgar, Moyiadi and Prakash, Shetty and Vikas, Singh and Nidhisha, Sadwani and Akshohini, Garg and Ayushi, Sahay and Abhishek, Chatterjee and Sridhar, Epari and Tejpal, Gupta and Archya, Dasgupta and Jayant, Goda},
title = {Patient‐Derived Glioblastoma Organoids for AI‐Guided Prediction of Therapeutic Response},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.78202}
}
EUVIMED